anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Children with hemato-oncological diseases or following stem cell transplantation (SCT) are at high risk for life-threatening infections; sepsis in this population constitutes a substantial proportion of pediatric intensive care unit (PICU) admissions. The current pediatric prognostic scoring tools to evaluate illness severity and mortality risk are designed for the general pediatric population and may not be adequate for this vulnerable subpopulation. Methods: Retrospective analysis was performed on all PICU admissions for sepsis in children with hemato-oncological diseases or post-SCT, in a single tertiary pediatric hospital between 2008 and 2021 (n = 233). We collected and analyzed demographic, clinical, and laboratory data and outcomes for all patients, and evaluated the accuracy of two major prognostic scoring tools, the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) and the Pediatric Risk of Mortality III (PRISM III). Furthermore, we created a new risk-assessment model that contains additional parameters uniquely relevant to this population. Results: The survival rate for the cohort was 83%. The predictive accuracies of PELOD-2 and PRISM III, as determined by the area under the curve (AUC), were 83% and 78%, respectively. Nine new parameters were identified as clinically significant: age, SCT, viral infection, fungal infection, central venous line removal, vasoactive inotropic score, bilirubin level, C-reactive protein level, and prolonged neutropenia. Unique scoring systems were established by the integration of these new parameters into the algorithm; the new systems significantly improved their predictive accuracy to 91% (p = 0.01) and 89% (p < 0.001), respectively. Conclusions: The predictive accuracies (AUC) of the PELOD-2 and PRISM III scores are limited in children with hemato-oncological diseases admitted to PICU with sepsis. These results highlight the need to develop a risk-assessment tool adjusted to this special population. Such new scoring should represent their unique characteristics including their degree of immunosuppression and be validated in a large multi-center prospective study.
Virtual control groups (VCGs) created from historical control data (HCD) can reduce the number of concurrent control group animals needed in regulatory toxicity studies by up to 25%. This study investigates the performance of VCGs on statistical outcomes of body weight development between treatment and control groups in legacy studies. The objective is to reproduce the statistical outcomes of 28-day sub-chronic studies (legacy studies) after replacing the concurrent control group with virtual ones. In rodent toxicity studies initial body weight is used as surrogate for the age of animals. For the assessment of VCG-sampling methods, three different approaches were explored: (i) sam­pling VCGs from the entire HCD, ignoring initial body weight information of the legacy study, (ii) sampling from HCD by matching the legacy study's initial body weights, and (iii) sampling from HCD with assigned statistical weights derived from legacy study initial body weight information. The ability to reproduce statistical outcomes using virtual controls was determined by the congruence between the legacy study and the HCD weight distribution: regardless of the chosen approach, the ability to reproduce statistical outcomes was high for VCGs when the legacy study's initial body weight distribution was similar to the HCD's. When the initial body weight range of the legacy study was at the extreme ends of the HCD's distribution, the weighted sampling approach was superior. This article demonstrates the importance of proper HCD matching by the legacy study's initial body weight and discusses conditions to accurately reproduce body weight development.
One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
The invention relates to construction and application of classical swine fever viruses, and aims to provide a classical swine fever virus with high reproductive capacity and a construction method thereof. The virus vaccine strain is preserved in China center for type culture collection, and the preservation name is CSFV-Cmut8 of a hog cholera virus low virulent strain fixed-point mutant strain, and the preservation number is CCTCC No: and V201744. The invention utilizes a reverse genetics method to obtain CSFV-Cmut8 by modifying specific 8 sites on the C strain genome. Compared with the maternal C strain, the virus can generate higher titer in vitro cultured cells, maintains stable genetic characteristics in the continuous passage process and has no pathogenicity to natural host pigs. The invention can improve the yield of the vaccine and reduce the cost, and can be used as a candidate vaccine strain for hog cholera immunization. The invention can be used for improving the cell adaptability of other vaccines taking the C strain as a framework, improving the virus rescue success rate and reducing the production cost of the classical swine fever cell vaccine.
PURPOSE:To obtain the subject new peptide capable of inhibiting angiotensinase having vasopressor activity and useful for a health food, a medical drug, etc., for prevention of hypertension by decomposing royal jelly using a protease. CONSTITUTION:Royal jelly protein is added to a phosphate buffer solution (pH2) and a protease such as pepsin is further added thereto. After decomposition of the protein by incubation at 37 deg.C for 24hr, the enzyme is inactivated by heat treatment in boiling water for 10min. The treated solution is then allowed to cool and subsequently centrifuged to remove the insoluble materials. The resultant supernatant is fractionated by a gel filtration and active fractions are passed through an adsorptive resin column. The adsorbed fraction is subjected to gradient elusion by using ammonium formate and its active fraction is then further purified by high performance liquid chromatography, etc., thus obtaining the objective new peptide having an amino acid sequence of the formula and having an angiotensinase inhibitory effect.
Safety and effectiveness of Risperidone for Extended-Release Injectable Suspension in pediatric patients have not been established. However, juvenile animal toxicology studies have been conducted with oral risperidone.

Juvenile Animal Studies

Juvenile dogs were treated with oral risperidone from weeks 10 to 50 of age (equivalent to the period of childhood through adolescence in humans), at doses of 0.31, 1.25, or 5 mg/kg/day, which are 1.2, 3.4 and 13.5 times the MRHD of 6 mg/day for children, based on mg/m2 body surface area. Bone length and density were decreased with a no-effect dose of 0.31 mg/kg/day; this dose produced plasma AUC of risperidone plus its active metabolite paliperidone (9-hydroxy-risperidone) that were similar to those in children and adolescents receiving the MRHD of 6 mg/day. In addition, sexual maturation was delayed at all doses in both males and females. The above effects showed little or no reversibility in females after a 12 week drug-free recovery period. Juvenile rats, treated with oral risperidone from days 12 to 50 of age (equivalent to the period of infancy through adolescence in humans) showed impaired learning and memory performance (reversible only in females), with a no-effect dose of 0.63 mg/kg/day which is 0.5 times the MRHD of 6 mg/day for children, based on mg/m2 body surface area. This dose produced plasma AUC of risperidone plus paliperidone about half the exposure observed in humans at the MRHD. No other consistent effects on neurobehavioral or reproductive development were seen up to the highest tested dose of 1.25 mg/kg/day which is 1 time the MRHD and produced plasma AUC of risperidone plus paliperidone that were about two thirds of those observed in humans at the MRHD of 6 mg/day for children.
FIELD: medicine, biochemistry. SUBSTANCE: invention relates to development of agents of vegetable origin designated for prophylaxis of atherosclerosis and decrease of serum blood cholesterol level. Invention proposes the agent for regulation of lipid metabolism that is the oat grains extract obtained by treatment of nonmilled grains with nonpolar extractant followed by separation of the end product and evaporation. Agent has lipid fraction with density value 0.760-0.925 g/cm 3  at 20 C, acid number 103.0- 110.0 mg of KOH/g, iodine number 132.0-140.0 and lipid fraction has 57-62% of free fatty acids and 27-32% and 25-29% of free fatty acid esters. Invention proposes also a method of preparing the agent used for regulation of lipid metabolism that involves treatment of nonmilled oat grains with nonpolar extractant in their ratio = (1: 2)-(1: 4) at temperature 40-70 C followed by separation and concentration of the end product. Solvent as nonpolar extractant taken among the following group is used: petroleum ether, hexane, diethyl ether, chloroform. Extraction is performed for 6-12 h and the end product is separated by filtration. Then the end product is concentrated by evaporation. The developed agent is designated for prophylaxis of atherosclerosis and body weight decrease. Every day administration of extract inhibits body mass gain for observation period. The prolonged administration of lipid extract does not result to changes in hemoglobin and erythrocytes content in peripheral blood of rats. In study of blood cells composition in these animals disturbances of leukocyte formula are absent as compared with control. Thus, the prolonged administration of agent does not offer damage effect on hemopoietic system of animals. Agent shows low allergenic activity. EFFECT: improved method of preparing, enhanced effectiveness of agent, valuable medicinal properties. 6 cl, 2 tbl
Spironolactone is rapidly and extensively metabolized. Sulfur-containing products are the predominant metabolites and are thought to be primarily responsible, together with spironolactone, for the therapeutic effects of the drug. The following pharmacokinetic data were obtained from 12 healthy volunteers following the administration of 100 mg of spironolactone (as tablets) daily for 15 days. On the 15th day, spironolactone was given immediately after a low fat breakfast and blood was drawn thereafter.

The pharmacological activity of spironolactone metabolites in man is not known. However, in the adrenalectomized rat the antimineralocorticoid activities of the metabolites C, TMS, and HTMS, relative to spironolactone, were 1.10, 1.28, and 0.32, respectively. Relative to spironolactone, their binding affinities to the aldosterone receptors in rat kidney slices were 0.19, 0.86, and 0.06, respectively.

In humans, the potencies of TMS and 7-α-thiospirolactone in reversing the effects of the synthetic mineralocorticoid, fludrocortisone, on urinary electrolyte composition were 0.33 and 0.26, respectively, relative to spironolactone. However, since the serum concentrations of these steroids were not determined, their incomplete absorption and/or first-pass metabolism could not be ruled out as a reason for their reduced in vivo activities.

Spironolactone and its metabolites are more than 90% bound to plasma proteins. The metabolites are excreted primarily in the urine and secondarily in bile.

The effect of food on spironolactone absorption (two 100 mg spironolactone tablets) was assessed in a single dose study of 9 healthy, drug-free volunteers. Food increased the bioavailability of unmetabolized spironolactone by almost 100%. The clinical importance of this finding is not known.

Hydrochlorothiazide is rapidly absorbed following oral administration. Onset of action of hydrochlorothiazide is observed within one hour and persists for 6 to 12 hours. Hydrochlorothiazide plasma concentrations attain peak levels at 1 to 2 hours and decline with a half-life of 4 to 5 hours. Hydrochlorothiazide undergoes only slight metabolic alteration and is excreted in urine. It is distributed throughout the extracellular space, with essentially no tissue accumulation except in the kidney.
This invention provides new systems and methods for controlling the operation of medical devices. Devices collect sensor data, relay such data as streaming data via a secure internet connection, but also collect such data locally as cache data. When events occur, such as an offline event, the devices also relay such cache data. Device data is received by a network data system that analyzes the data and controls operation of the devices and other network devices based on such analysis. The medical devices can comprise multiple zones performing different data collection functions and being subject to different data relay rules/processes. The system can segregate protected health information from commercial users that are allowed to access certain analytical data. In aspects, the system interacts with third party databases, e.g., customer relationship management systems, in generating analytical data. In aspects, machine learning processes are employed to improve the operation of such systems.
Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
An automobile monitoring system is for monitoring patient body- characteristics . The automobile monitoring system includes at least one sensor (9) to monitor at least one patient body characteristic, at least one transmitter (7) operatively coupled to the at least one sensor to communicate sensor data, at least one monitor (5) operatively coupled to the at least one transmitter to receive the sensor data, and automobile electronics (19) operatively coupled to the at least one transmitter to receive sensor data. The at least one monitor and the automobile electronics display the sensor data to the patient. The at least one transmitter communicates with the at least one monitor and the automobile electronics using at least one wireless protocol including Bluetooth, infrared, radio frequency, 802.11a, 802.11b, or 802. Hg. The automobile electronics include at least one of a GPS navigation system, a DVD entertainment system, an on-system computer, or a stereo system.
AIMS: Autophagy is an important cellular process for maintaining physiological homeostasis and is known to protect against cardiovascular diseases including ischemia reperfusion (I/R) injury. The underlying mechanisms behind its protection require further characterization.
MATERIALS AND METHODS: Atg7 knock out (AKO) mice were generated and subjected to I/R injury, complemented by Atg7 KO in a H9c2 cardiomyoblast cellular model ± hypoxia-reoxygenation. Subsequently, in both models, inflammation and cell death were studied.
KEY FINDINGS: We confirmed that Atg7 KO led to autophagy, including mitophagy, deficiency. Upon H/R, Atg7 KO cells exhibited increased cell death compared to WT cells. Notably, we found that autophagy deficiency increased stress-induced mitochondrial fission, release of mitochondrial DNA, and sterile inflammation, namely activation of a STING/IRF3 axis leading to elevated interferon-α. Following I/R injury, AKO mice showed elevated cell death which correlated with a gene expression profile indicative of decreased anti-inflammatory responses.
SIGNIFICANCE: Autophagy deficiency in the cardiomyocyte setting results in detrimental effects during I/R injury in mice or H/R injury in cells, mediated in part via mtDNA/IRF3/STING pathway. As such, modulation of this pathway may yield novel and promising therapeutics to treat or prevent I/R injury.
PURPOSE: A composition for preventing or treating immunological rejection diseases including IL-27 is provided to alleviate the immunological rejection disease by suppressing rejection towards the host after the transplanted cell or organ is engrafted. CONSTITUTION: A composition for preventing or treating immunological rejection diseases includes IL-27 as an active component. The IL-27 has amino acid sequence described in the sequence number 1(SEQ ID NO:1). The composition for preventing or treating immunological rejection diseases includes a vector containing polynucleotide which codes the IL-27 as an active ingredient. The polynucleotide has the base sequence described in the sequence number 2. The immunological rejection disease is graft-versus-host disease.
Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.
FIELD: medicine. SUBSTANCE: method involves administering Tripolite as sorbent agent having particle sizes not greater than 0.8 mm through a probe. The amount is equal to 20-50 g per 150-200 ml of water. The procedure is applied 1-2 times a day with 2-5 h pause. EFFECT: enhanced effectiveness of toxin sorption; accelerated exit from coma state. 2 cl
PURPOSE: To investigate the test-retest reliability and construct validity of the LCADL scale applied via online form in individuals after hospitalization for COVID-19.
METHODS: Methodological study. After hospitalization for COVID-19 individuals completed the LCADL via online form at two separate times. They also answered the post-COVID-19 Functional Status Scale (PCFS), dyspnea, fatigue, and health perception scales, modified Medical Research Council (MRCm), Short Form Health Survey 36 (SF-36). Hospitalization data were collected from the individual's medical record.
RESULTS: 104 individuals participated in the study (57 men, 45.2 ± 11.9 years). The LCADL showed moderately to high test-retest reliability (ICC: 0.73-0.86; p < 0.001), there was no difference in scores between test and retest (p > 0.05), the mean difference between the applications was smaller than the standard error of measurement and the internal consistency was adequate (Cronbach's α = 0.70-0.94). In addition, it demonstrated adequate construct validity, showing correlations with PCFS, dyspnea perception, fatigue and health scales, mMRC, SF-36, and length of stay in the Intensive Care Unit (p < 0.05). The LCADL as percentage of the total score presented a significant floor effect (25%).
CONCLUSION: The LCADL applied online was reliable and valid for assessing limitations due to dyspnea in ADL in individuals after hospitalization for COVID-19.
Composition and methods which include a dental bleaching agent and potassium nitrate for enhanced whitening and reduced tooth sensitivity. The potassium nitrate both enhances the whiteness of teeth beyond the whitening effect of the dental agent and reduces or eliminates tooth sensitivity that would otherwise be caused by the bleaching agent. For prolonged treatment of teeth, lower quantities of potassium nitrate (e.g., 0.5 %) have actually been found to work better than larger quantities (e.g., 3 %). The dental compositions (40) may be applied directly to the person's teeth, or they may be loaded into a comfortable fitting, flexible, thin-walled dental tray (50) and placed over the person's teeth. In that case, the dental compositions (40) will include a tackifying agent, such as carboxypolymethylene, which assists the composition in retaining the dental tray (50) over the person's teeth as a result of the adhesive properties of the dental composition (40) rather than due to mechanical interlocking of the tray (50) over the person's teeth. The dental compositions may further include anticariogenic and antimicrobial agents.
Acute neck pain is often caused by mechanical causes and can be classified as rheumatic diseases, infectious and tumoral pathologies, metabolic bone diseases such as osteoporosis and osteomalacia, pain reflected the cervical region. A-V malformation and syringomyelia are the causes of chronic cervical pain (5). Mechanical neck pain is a non-radicular pain caused by local musculoskeletal structures and is characterized by a spasm of the cervical muscles. (6, 7). Posture, emotional stress, cold and fatigue are etiologic causes, and pain is also reflected in the cervical, occipital and scapular regions depending on the severity of muscle spasm and the presence of trigger point in myofascial pain syndrome (9, 10). Many authors have suggested that facet joints are associated with mechanical dysfunction as a common cause of cervical pain (8-10).

The pain in the head and neck region affects the quality of life, cognitive and functional status of the person. The most important difficulty and failure in the treatment of such pain arise from the inability to diagnose the disease correctly. Good anatomical and biomechanical properties of the region, comprehensive anamnesis, physical examination under static and dynamic conditions, laboratory and radiological examinations are the most important milestones of diagnosis (12). In most cases, medical treatment and physical therapy modalities (superficial and deep heat, electrotherapy, laser, traction, massage, spa) are sufficient for pain relief and recovery of function, but interventional procedures and surgical procedures are needed for the fewer patient. Recently, spinal mobilization and manipulation techniques can be used to relieve pain and restore function in the early stages. Although it is a safe method, in order to prevent the rare complications it is necessary to determine the indications of treatment correctly, to exclude contiguous cases and to apply the manipulation by experts (12).
Clinical experience with pentazocine hydrochloride and acetaminophen tablets has been insufficient to define all possible adverse reactions with this combination. However, reactions reported after oral administration of pentazocine hydrochloride in 50 mg dosage include gastrointestinal: nausea, vomiting, infrequently constipation; and rarely abdominal distress, anorexia, diarrhea. CNS effects: dizziness, lightheadedness, hallucinations, sedation, euphoria, headache, confusion, disorientation; infrequently weakness, disturbed dreams, insomnia, syncope, visual blurring and focusing difficulty, depression; and rarely tremor, irritability, excitement, tinnitus. Autonomic: sweating; infrequently flushing; and rarely chills. Allergic: infrequently rash; and rarely urticaria, edema of the face. Cardiovascular: infrequently decrease in blood pressure, tachycardia. Hematologic: rarely depression of white blood cells (especially granulocytes), which is usually reversible, moderate transient eosinophilia. Other: rarely respiratory depression, urinary retention, paresthesia, serious skin reactions, including erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, and in one instance, an apparent anaphylactic reaction has been reported.

Numerous clinical studies have shown that acetaminophen, when taken in recommended doses, is relatively free of adverse effects in most age groups, even in the presence of a variety of disease states.

A few cases of hypersensitivity to acetaminophen have been reported, as manifested by skin rashes, thrombocytopenic purpura, rarely hemolytic anemia and agranulocytosis. Occasional individuals respond to ordinary doses with nausea and vomiting and diarrhea.